更新的年龄相关性黄斑变性多基因风险评分的预测性能
在4175名70岁及以上欧洲裔参与者中,更新的PRS2023对年龄相关性黄斑变性(AMD)的预测性能优于PRS2016,并与晚期AMD风险升高相关。包含PRS2023的模型预测晚期AMD的AUC为91%,较不含PRS的模型提高12%。
要点
- PRS2023高分(最高四分位)者中超过27%患有中期或晚期AMD。
- PRS2023与晚期AMD相关,每标准差调整OR为5.05(95%CI 3.41-7.47)。
- PRS2023预测性能优于PRS2016(DeLong检验P=0.03)。
核心结论
- 更新的PRS2023对AMD的预测性能优于先前的PRS,并可预测晚期AMD风险升高,且与越严重的影像确诊AMD分级关联越强。
研究设计与样本
- 横断面研究,纳入4175名70岁及以上、具有基因型和视网膜影像数据的欧洲裔参与者。
主要发现
- 入组时2605名(62.4%)无AMD,853名(20.4%)、671名(16.1%)、46名(1.1%)分别为早期、中期和晚期AMD。
- PRS2023最高四分位者中超过27%患有中期或晚期AMD,中间两个四分位者中低于15%,最低四分位者中低于13%。
- PRS2023和PRS2016在调整年龄、性别、吸烟状态和血脂水平后均与AMD显著相关,且OR随AMD分级加重而升高。
- PRS2023预测所有AMD和晚期AMD的AUC均优于PRS2016(DeLong检验P=0.03)。
- PRS2023与晚期AMD相关,每标准差调整OR为5.05(95%CI 3.41-7.47)。
临床怎么用
- 作者认为,该发现对AMD的改进预测和风险分层具有临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A recent genome-wide association study of age-related macular degeneration (AMD) identified new AMD-associated risk variants. These variants now can be incorporated into an updated polygenic risk score (PRS). This study aimed to assess the performance of an updated PRS, PRS2023, in an independent cohort of older individuals with retinal imaging data and to compare performance with an older PRS, PRS2016. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 4175 participants of European ancestry, 70 years of age or older, with genotype and retinal imaging data. METHODS: We used logistic regression models and area under the receiver operating characteristic curve (AUC) to assess the performance of PRS2023 compared with PRS2016. AMD status and severity were graded using color fundus photography. MAIN OUTCOME MEASURES: Association of PRS2023 and PRS2016 with AMD risk at baseline. RESULTS: At enrollment among 4175 participants, 2605 participants (62.4%) had no AMD and 853 participants (20.4%), 671 participants (16.1%), and 46 participants (1.1%) had early, intermediate, and late-stage AMD, respectively. More than 27% of the participants with a high PRS2023 (top quartile) had intermediate or late-stage AMD, compared with < 15% for those in the middle 2 quartiles and less than 13% for those in the lowest quartile. Both PRS2023 and PRS2016 were associated significantly with AMD after adjustment for age, sex, smoking status, and lipid levels, with increasing odds ratios (ORs) for worsening AMD grades. PRS2023 outperformed PRS2016 (P = 0.03 for all AMD and P = 0.03 for late AMD, DeLong test comparing AUC). PRS2023 was associated with late-stage AMD with an adjusted OR of 5.05 (95% confidence interval [CI], 3.41-7.47) per standard deviation. The AUC of a model containing conventional or nongenetic risk factors and PRS2023 was 91% (95% CI, 87%-95%) for predicting late-stage AMD, which improved 12% over the model without the PRS (AUC, 79%; P < 0.001 for difference). CONCLUSIONS: A new PRS, PRS2023, for AMD outperforms a previous PRS and predicts increasing risk for late-stage AMD (with stronger association for more severe imaging-confirmed AMD grades). Our findings have clinical implications for the improved prediction and risk stratification of AMD. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Yu C, Robman L, He W, et al. Predictive Performance of an Updated Polygenic Risk Score for Age-Related Macular Degeneration. Ophthalmology. 2024. PMID: 38307466. doi:10.1016/j.ophtha.2024.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。